Cardiol Therapeutics sets up at-the-market share offering of up to US$75 million with Jefferies
CRDL•Cardiol Therapeutics entered an equity distribution agreement with Jefferies for an at-the-market offering of up to US$75 million in common shares. The company has no obligation to sell shares, and proceeds would support drug development and general corporate expenses.
1. Offering terms
Cardiol Therapeutics entered an equity distribution agreement with Jefferies for an at-the-market offering of up to US$75 million in common shares. Shares may be sold at prevailing market prices, but the company has no obligation to sell.
2. Planned use of proceeds
Net proceeds will support CardiolRx development for recurrent pericarditis, CRD-38 clinical development and general corporate expenses.
